Biofil Chemicals & Pharmaceuticals share news, announcements and annual reports
NSE: BIOFILCHEMBSE: 524396Pharmaceuticals & BiotechnologySmall Cap
Biofil Chemicals & Pharmaceuticals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1994 on BSE, Jun 1996 on NSE
Last close ₹28.68down ₹0.73 (2.48%)BSE ₹29.00
Share price at the NSE close on 30 Oct 2026. Previous close ₹29.41.
30 Oct: open ₹29.00, high ₹29.80, low ₹28.26
52-week range of traded prices to 30 Oct 2026
₹25.60Low, 30 Mar 2026₹46.34High, 3 Feb 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹47 Cr3,363rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 96.41
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.16
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 2.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 2.1%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.14
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,71974.4% delivered
Biofil Chemicals & Pharmaceuticals shareholder meetings
55 filed, newest first. Page 2 of 2.
Mar 2011
23 Mar · Meeting
An Extra-ordinary General Meeting held on March 23, 2011 the members of the company have passed special resolution for re-issuance of forfeited 5712500 equity shares subject to confirmation of appropriate authority.
Oct 2010
5 Oct · Meeting
Annual General Meeting of the Company was held on September 28, 2010. The resolutions as set out in the notice dated July 31, 2010 for following transactions were passed unanimously: (1) Adoption of the Audited Balance Sheet as at March 31, 2010 and Profit and Loss Account for the year ended March 31, 2010 and the Reports of the Directors and Auditors thereon. (2). Re-appointment of Mr. Ramesh Chimanlal Shah who retire by rotation. (3). Re-appointment M/s. S.N. Gadiya & Company, Chartered Accountants, Indore as Statutory Auditors of the Company from the conclusion of this Annual General Meeting to the conclusion of the next Annual General Meeting.
Oct 2009
5 Oct · Meeting
Biofil Chemicals & Pharmaceuticals Ltd. has informed the Exchange rearding the outcome of Annual General meeting held on September 30, 2009. The resolutions as set out in the notice dated August 25, 2009 for following transactions were passed unanimously: (1) Adoption of the Audited Balance Sheet as at March 31, 2009 and Profit and Loss Account for the year ended March 31, 2009 and the Reports of the Directors and Auditors thereon. (2). Re-appointment of Mr. Navneet Bagree who retire by rotation. (3). Appointment M/s. S.N. Gadiya & Company, Chartered Accountants, Mumbai as Statutory Auditors of the Company from the conclusion of this Annual General Meeting to the conclusion of the next Annual General Meeting.
Jan 2008
18 Jan · Meeting
Biofil Chemicals & Pharmaceuticals Ltd. has informed the Exchange that pursuant to section 293(1)(a) and 192A of the companies Act, 1956 read with the Companies (Passing of Resolution by Postal Ballot) Rules, 2001 and any amendments thereto, the following resolution is to be approved by the shareholders of the Company by way of an ordinary resolution and passed by Postal Ballot: Ordinary resolution under section 293(1)(a) of the Companies Act, 1956 in relation to authorization to board to sell the unit situated at Sanwer Road, Indore. The Company has appointed Mr. L.N. Joshi Company Secretaries, as Scrutinizer to scrutinize the Postal Ballots in a fair and transparent manner. The duly completed postal ballot forms should reach the scrutinizer before the close of working hours, on or before, January 28, 2008. The result of postal ballot will be announced by the Chairman on January 31, 2008. A copy of the Notice of Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.